HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients
Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis, prognosis, and follow-up. The purpose of this study was to evaluate whether serum HE4 was related to clinicopathological risk factors and outcome. Second, the role of serum HE4 and CA125 was assessed as indicator...
Saved in:
| Main Authors: | Karin Abbink, Petra LM Zusterzeel, Anneke J Geurts-Moespot, Antonius E van Herwaarden, Johanna MA Pijnenborg, Fred CGJ Sweep, Leon FAG Massuger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-02-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428318757103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison Between HE4, CA-125, and Combination of Both HE4 and CA-125 as Tumor Markers for Epithelial Ovarian Carcinoma Patients
by: PUNGKY MULAWARDHANA, et al.
Published: (2012-04-01) -
Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer
by: Nabil Abdalla, et al.
Published: (2017-01-01) -
Clinical significance of human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the risk of ovarian malignancy algorithm (ROMA), and Copenhagen index (CPH-I) for the diagnosis of endometrial carcinoma
by: Vesselina Koleva, et al.
Published: (2025-02-01) -
Meigs’ syndrome with elevated CA-125 and HE-4: a case report and literature review
by: Jichang Seong, et al.
Published: (2025-02-01) -
Prognosis of premenopausal women with low-risk endometrial cancer but elevated CA125 levels
by: Jeong Min Song, et al.
Published: (2025-01-01)